title: Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation.
abstract: OBJECTIVE
  We assessed 5 risk stratification schemes for their ability to predict atrial fibrillation (AF)-related thromboembolism in a large community-based cohort.
  
  
  BACKGROUND
  Risk schemes can help target anticoagulant therapy for patients at highest risk for AF-related thromboembolism. We tested the predictive ability of 5 risk schemes: the Atrial Fibrillation Investigators, Stroke Prevention in Atrial Fibrillation, CHADS(2) (Congestive heart failure, Hypertension, Age >or= 75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack) index, Framingham score, and the 7th American College of Chest Physicians Guidelines.
  
  
  METHODS
  We followed a cohort of 13,559 adults with AF for a median of 6.0 years. Among non-warfarin users, we identified incident thromboembolism (ischemic stroke or peripheral embolism) and risk factors from clinical databases. Each scheme was divided into low, intermediate, and high predicted risk categories and applied to the cohort. Annualized thromboembolism rates and c-statistics (to assess discrimination) were calculated for each risk scheme.
  
  
  RESULTS
  We identified 685 validated thromboembolic events that occurred during 32,721 person-years off warfarin therapy. The risk schemes had only fair discriminating ability, with c-statistics ranging from 0.56 to 0.62. The proportion of patients assigned to individual risk categories varied widely across the schemes. The proportion categorized as low risk ranged from 11.7% to 37.1% across schemes, and the proportion considered high risk ranged from 16.4% to 80.4%.
  
  
  CONCLUSIONS
  Current risk schemes have comparable, but only limited, overall ability to predict thromboembolism in persons with AF. Recommendations for antithrombotic therapy may vary widely depending on which scheme is applied for individual patients. Better risk stratification is crucially needed to improve selection of AF patients for anticoagulant therapy.
authors.affiliation: Department of Medicine, University of California at San Francisco, San Francisco, California, USA. mfang@medicine.ucsf.edu
authors.forename: Margaret C
authors.initials: MC
authors.lastname: Fang
authors.forename: Alan S
authors.initials: AS
authors.lastname: Go
authors.forename: Yuchiao
authors.initials: Y
authors.lastname: Chang
authors.forename: Leila
authors.initials: L
authors.lastname: Borowsky
authors.forename: Niela K
authors.initials: NK
authors.lastname: Pomernacki
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Singer
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods*; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology*